(2,4-dioxothiazolidin-3-yl)acetic acid tert-butyl ester | 50773-27-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2,4-dioxothiazolidin-3-yl)acetic acid tert-butyl ester
• 英文别名: t-butyl 2,4-dioxothiazolidine-3-acetate；Tert-butyl 2-(2,4-dioxo-1,3-thiazolidin-3-yl)acetate；tert-butyl 2-(2,4-dioxo-1,3-thiazolidin-3-yl)acetate
• CAS: 50773-27-8
• 化学式: C₉H₁₃NO₄S
• mdl: MFCD25963955
• 分子量: 231.273
• InChiKey: BKUAQGWOPUHCQD-UHFFFAOYSA-N

物化性质

• 沸点：
  321.2±44.0 °C(Predicted)
• 密度：
  1.289±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  89
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2,4-dioxothiazolidin-3-yl)acetic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 (2,4-二氧代-噻唑啉-3-基)-乙酸
  参考文献：
  名称：

  Discovery of a novel submicromolar inhibitor of the lymphoid specific tyrosine phosphatase

  摘要：

  We report here a class of thiazolidine-2,4-diones and 2-thioxothiazolidin-4-ones as potent inhibitors of the lymphoid specific tyrosine phosphatase (Lyp) identified from high throughput screens. Chemical modi. cation by incorporating the known phosphotyrosine (pTyr) mimics led to the discovery of a salicylate-based inhibitor with submicromolar potency. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.03.079
• 作为产物：
  描述：

  2,4-噻唑烷二酮 、 溴乙酸叔丁酯 在 sodium hydride 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 3.0h， 以78%的产率得到(2,4-dioxothiazolidin-3-yl)acetic acid tert-butyl ester
  参考文献：
  名称：

  某些新的含吡唑环系统的噻唑烷衍生物的合成及生物活性

  摘要：

  作为系统研究含吡唑环系统的噻唑烷（TZD）衍生物的合成和生物活性化合物的一部分，已经合成了几种新的吡唑-TZD衍生物8a，8b，8c，8d和9a，9b，9c，9d。化合物8a，8b，8c，8d由N取代的TZD 6a，6b，6c，6d和1 H-吡唑-4-甲醛7制备通过Knoevenagel型反应。在室温下用氢化钠处理8a，8b，8c，8d引起二聚反应，得到相应的螺化合物9a，9b，9c，9d。通过光谱分析对所有合成的化合物进行表征。在体外，合成的化合物8a，8b，8c，8d和9a，9b，9c，9d测试了它们在A549肺癌，B16F10鼠黑色素瘤和HeLa人子宫癌细胞中的生长抑制活性，以及​​将3T3-L1前脂肪细胞分化为脂肪细胞的能力。结果表明，化合物8c具有抑制B16F10细胞生长的作用（IC 50 = 27μM），化合物9c，9d具有诱导3T3-L1前脂肪细胞分化的作用。J.杂环化​​学。（2011）。

  DOI：

  10.1002/jhet.834

文献信息

• [EN] FUSED 1,3-AZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DÉRIVÉS FUSIONNÉS DE 1,3-AZOLE UTILES POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES
  申请人：MASSACHUSETTS INST TECHNOLOGY

  公开号：WO2016094688A1

  公开（公告）日：2016-06-16

  The present disclosure provides compounds of Formula (I-a), Formula (I), and Formula (II),. The compounds described herein may be Myc modulators (e.g., Myc inhibitors) and may be useful in treating in a subject in need thereof diseases associated with Myc and proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including a compound described herein. (Formulae (I-a), (I), (II))

  本公开提供了式(I-a)、式(I)和式(II)的化合物。本文描述的化合物可能是Myc调节剂（例如，Myc抑制剂），并且可能在治疗与Myc和增殖性疾病（例如癌症）相关的患者中有用。本公开还提供了包括本文描述的化合物的药物组合物、试剂盒、方法和用途。（式(I-a)、(I)、(II)）
• Thiazole derivatives, their preparation and their use in the treatment
  申请人：Sankyo Company Limited

  公开号：US04933355A1

  公开（公告）日：1990-06-12

  Compounds of formula (I): ##STR1## in which: R.sup.1 and R.sup.2 are independently hydrogen, alkyl, aliphatic hydrocarbon groups having one or two carbon-carbon double or treble bonds, cycloalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, alkanoyl, alkenyol, cycloalkylcarbonyol, arylcarbonyl, substituted arylcarbonyl, arylalkanoyl, substituted arylalkanoyl, arylalkenoyl, substituted arylalkenoyl, alkoxycarbonyl, aryloxycarbonyl, substituted aryloxycarbonyl, aralkyloxycarbonyl, substituted aralkyloxycarbonyl, optionally substituted carbamoyl or thiocarbamoyol, alkylsulfonyl, haloalkylsulfonyl, arylsulfonyl, substituted arylsulfonyl, alkylthio, arylthio and substituted arylthio, or R.sup.1 and R.sup.2, together with the nitrogen atom to which they are attached, form a nitrogen-containing heterocyclic group; one of R.sup.a and R.sup.b is hydrogen, alkyl or halogen, and the other of R.sup.a and R.sup.b is a group of formula (II): ##STR2## R.sup.4 is hydrogen, carboxy, protected carboxy or optionally substituted carbamoyl; R.sup.5 is hydrogen, or carboxyalkyl or protected carboxyalkyl in which the alkyl part is C.sub.1 -C.sub.6 ; n=0, 1 or 2; X is oxygen or sulfur; are useful in the treatment of the complications attendant upon diabetes and may be prepared by condensation of a thiazolidine or rhodanine compound with a compound corresponding to the remainder of the molecule of the compound of formula (I).

  式(I)的化合物：##STR1##其中：R.sup.1和R.sup.2分别是氢、烷基、具有一个或两个碳-碳双键或三键的脂肪烃基、环烷基、芳基、取代的芳基、芳基烷基、取代的芳基烷基、烷酰基、烯酰基、环烷基羰基、芳基羰基、取代的芳基羰基、芳基烷酰基、取代的芳基烷酰基、芳基烯酰基、取代的芳基烯酰基、烷氧羰基、芳氧羰基、取代的芳氧羰基、芳基烷氧羰基、取代的芳基烷氧羰基、可选地取代的氨基甲酰基或硫代氨基甲酰基、烷磺酰基、卤代烷基磺酰基、芳基磺酰基、取代的芳基磺酰基、烷硫基、芳硫基和取代的芳硫基，或R.sup.1和R.sup.2与它们连接的氮原子一起形成含氮杂环基团；R.sup.a和R.sup.b中的一个是氢、烷基或卤素，另一个是具有式(II)的基团：##STR2##R.sup.4是氢、羧基、保护羧基或可选地取代的氨基甲酰基；R.sup.5是氢，或者是碳链部分为C.sub.1-C.sub.6的羧基烷基或保护羧基烷基；n=0, 1或2；X是氧或硫；这些化合物在治疗糖尿病并发症方面是有用的，可以通过将噻唑烷或罗丹宁化合物与符合式(I)的化合物的分子余下部分对应的化合物缩合来制备。
• MYC MODULATORS AND USES THEREOF
  申请人：Massachusetts Institute of Technology

  公开号：US20160168165A1

  公开（公告）日：2016-06-16

  The present disclosure provides compounds of Formula (I-a), Formula (I), and Formula (II). The compounds described herein may be Myc modulators (e.g., Myc inhibitors) and may be useful in treating in a subject in need thereof diseases associated with Myc and proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including a compound described herein.

  本公开提供式(I-a)、式(I)和式(II)的化合物。本文所描述的化合物可能是Myc调节剂（例如Myc抑制剂），并且可能有用于治疗与Myc和增殖性疾病（例如癌症）相关的患者。本公开还提供了包括所述化合物的药物组合物、试剂盒、方法和用途。
• Thiazole derivatives, their preparation and their use in the treatment of diabetes complications
  申请人：Sankyo Company Limited

  公开号：EP0337819A1

  公开（公告）日：1989-10-18

  Compounds of formula (I): in which: R1 and R2 are independently hydrogen, alkyl, aliphatic hydrocarbon groups having one or two carbon-carbon double or treble bonds, cycloalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, alkanoyl, alkenoyl, cycloalkylcarbonyl, arylcarbonyl, substituted arylcaronyl, arylalkanoyl, substituted arylalkanoyl, arylalkenoyl, substituted arylalkenoyl, alkoxycarbonyl, aryloxycarbonyl, substituted aryloxycarbonyl, aralkyloxycarbonyl, substituted aralkyloxycarbonyl, optionally substituted carbamoyl or thiocarbamoyl, alkylsulphonyl, haloalkylsulphonyl, arylsulphonyl, substituted arylsulphonyl, alkylthio, arylthio and substituted arylthio, or R1 and R2, together with the nitrogen atom to which they are attached, form a nitrogen-containing heterocyclic group; one of Ra and Rb is hydrogen, alkyl or halogen, and the other of Ra and Rb is a group of formula (II): R4 is hydrogen, carboxy, protected carboxy or optionally substituted carbamoyl; R5 is hydrogen, or carboxyalkyl or protected carboxyalkyl in which the alkyl part is C1 -Cs; n = 0, 1 or 2; X is oxygen or sulphur; are useful in the treatment of the complications attendant upon diabetes and may be prepared by condensation of a thiazolidine or rhodanine compound with a compound corresponding to the remainder of the molecule of the compound of formula (I).

  式(I)化合物： 其中 R1 和 R2 独立地为氢、烷基、具有一个或两个碳碳双键或三键的脂族烃基、环烷基、芳基、取代芳基、烷酰基、烯酰基、环烷基羰基、芳基羰基、取代芳基羰基、芳基烷酰基、取代芳基烷酰基、芳基烯酰基、取代芳基烯酰基、烷氧基羰基、芳氧基羰基、芳氧基羰基、芳烷氧基羰基、取代芳氧基羰基、芳烷氧基羰基、芳烷氧基羰基、取代芳烷氧基羰基、选择性取代氨基甲酰基或硫代氨基甲酰基、烷氧基羰基、芳氧基羰基、取代的芳氧基羰基、烷氧基羰基、取代的芳氧基羰基、任选取代的氨基甲酰基或硫代氨基甲酰基、烷基磺酰基、卤代烷基磺酰基、芳基磺酰基、取代的芳基磺酰基、烷硫基、芳硫基和取代的芳硫基，或 R1 和 R2 与它们所连接的氮原子一起形成含氮杂环基团；Ra 和 Rb 中的一个是氢、烷基或卤素，Ra 和 Rb 中的另一个是式 (II) 基团： R4 是氢、羧基、受保护的羧基或任选取代的氨基甲酰基；R5 是氢、羧基烷基或受保护的羧基烷基，其中烷基部分是 C1-Cs；n = 0、1 或 2；X 是氧或硫； 可通过噻唑烷或罗丹宁化合物与对应于式（I）化合物分子剩余部分的化合物缩合制备。
• Myc modulators and uses thereof
  申请人：Massachusetts Institute of Technology

  公开号：US10017520B2

  公开（公告）日：2018-07-10

  The present disclosure provides compounds of Formula (I-a), Formula (I), and Formula (II). The compounds described herein may be Myc modulators (e.g., Myc inhibitors) and may be useful in treating in a subject in need thereof diseases associated with Myc and proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including a compound described herein.

  本公开提供了式(I-a)、式(I)和式(II)化合物。本文所述的化合物可以是Myc调节剂（如Myc抑制剂），可用于治疗有需要的受试者与Myc相关的疾病和增殖性疾病（如癌症）。本公开还提供了包括本文所述化合物的药物组合物、试剂盒、方法和用途。